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Novel anticancer agents in clinical and preclinical trials
Adnan Salim1

Editorial
Billions of people worldwide are affected with various forms of cancer of virtually any part of the human body. Despite vast amounts of
funds being poured into cancer research, the production of a single
drug, or a group of drugs, which may ‘cure’ cancer remains an elusive
dream. The future is not so bleak, though. Many drugs have been
approved recently which combat the cancerous growth and alleviate
quality of life of the patient. Countless others are under trials. What
follows is an attempt to summarize a few.
Akt, or protein kinase B (PKB), is a serine/threonine protein kinase
which acts as a mediator in many cellular processes. Three members
in the Akt family have been identified until now, of which Akt1 is the
molecule playing a key role in cell survival and metabolism. It acts
mainly via the activation of receptor tyrosine kinases (RTK), and produces such effects as inhibition of apoptosis, promotion of cell cycle
progression and stimulation of angiogenesis. Miltefosine is the only
Akt inhibitor which has been approved (that too for leishmaniasis),
while several others show promise in their pre-clinical trials. These
have been divided into different classes according to their mode of
actions, and some, like Perifosine have failed too. [1].
Poly(ADP-ribose) Polymerases (PARPs) are a group of 17 proteins
which play a role in apoptosis, genetic maintenance, inflammatory
responses and regulation of gene transcription. PARP inhibitors were
developed as agents that seem to target cancer cells when they are
undergoing DNA repair [2]. Olaparib (AZD2281) showed anti-tumor
effects in patients with BRCA1/2 mutated cancers. Patients showed
40% response rate in platinum sensitive ovarian cancer with
germline BRCA1/2 mutations [3]. Rucaparib, another PARP inhibitor
showed promising results with chemopotention when used with temozolomide for metastatic melanoma [4].
c-Met is a proto-oncogene that encodes hepatocyte growth factor
receptor (HGFR) [5]. It plays an important role in embryonic development, organ morphogenesis and healing reactions [6]. Met is a
membrane receptor stimulating cell motility, invasion, protection
from apoptosis and angiogenesis. Dysregulated activity of c-Met can
cause a wide variety of cancers, including colorectal, gastric carcinoma, liver, thyroid, breast, pancreas, renal cell, ovary, prostate and
melanoma [7]. c-Met inhibitors are quite recent drugs. Foretinib
XL880 completed phase 2 clinical trial with indications for head and
neck, gastric and renal cell carcinoma and is still experimental [8].
Cabozantinib (XL184) was approved by the U.S. Food and Drug Authority in November 2012 for the treatment of medullary thyroid
cancer. There are several drugs of this category undergoing trials and
there is promise shown that these used in conjunction with other
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chemotherapeutic agents will significantly alter the course of the disease [7].
Imatinib, a tyrosine Kinase Inhibitor, is being used widely for the
treatment of chronic myeloid leukemia (CML) [9]. Nilotinib, Dasatinib, Bosutinib and Ponatinib are newer drugs of this class approved for the treatment of imatinib resistant or intolerant CML [10,
11].
Histone de-acetylase inhibitors (HDIs) are yet another class of futuristic anti-cancer drugs bring used. [12]. Vorinostat (SAHA) and romidepsin (ISTODAX) are FDA approved for the treatment of cutaneous T cell lymphoma. Use of HDIs as other types of cancer shows
moderate effects [13, 14].
Vismodegib, a hedgehog pathway inhibitor has been recently approved for treatment of advanced basal cell carcinoma [15]. Cyclopamine is the prototype inhibitor of the Sonic Hedgehog (Shh) pathway and is currently undergoing preclinical and clinical studies as an
agent in treatment of basal cell carcinoma, medulloblastoma and
rhabdomyosarcoma [16, 17]. Saridegib, a synthetic analog of cyclopamine, has shown encouraging results in phase I trial of advanced
solid tumors [18, 19].
Heat Shock Protein (HSP) inhibitors, drugs which inhibit molecular
chaperones, though still in phase II clinical trials, show promise in the
treatment of a variety of malignancies [20].
Many rounds of preclinical and clinical trials are still needed to determine accurately the potential of anticancer medicines. While
many may show promise, there is still the question of their therapeutic indices and toxicity profiles. Some of these agents may stop or
revert the growth of a tumor but may adversely affect the patient’s
health otherwise. Chemotherapy is an exciting and ever-growing
field of research and intense work is being done which promises
hope for health professionals and for the affected.
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